128 related articles for article (PubMed ID: 38547774)
21. Selumetinib for the treatment of metastatic uveal melanoma: past and future perspectives.
Komatsubara KM; Manson DK; Carvajal RD
Future Oncol; 2016 Jun; 12(11):1331-44. PubMed ID: 27044592
[TBL] [Abstract][Full Text] [Related]
22. A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer.
Deming DA; Cavalcante LL; Lubner SJ; Mulkerin DL; LoConte NK; Eickhoff JC; Kolesar JM; Fioravanti S; Greten TF; Compton K; Doyle AG; Wilding G; Duffy A; Liu G
Invest New Drugs; 2016 Apr; 34(2):168-75. PubMed ID: 26666244
[TBL] [Abstract][Full Text] [Related]
23. Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma.
Patel SP; Lazar AJ; Papadopoulos NE; Liu P; Infante JR; Glass MR; Vaughn CS; LoRusso PM; Cohen RB; Davies MA; Kim KB
Cancer; 2013 Feb; 119(4):799-805. PubMed ID: 22972589
[TBL] [Abstract][Full Text] [Related]
24. Canadian Cancer Trials Group (CCTG) IND215: A phase Ib study of Selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimens.
Goffin JR; Nicholas G; Mates M; Tu D; Chen E; Laurie SA; Juergens R; Robinson A; Goss G; Reaume M; Sun S; Christink K; Maize C; MacFarlan S; Sun X; Ritter H; Seymour L; Bradbury PA
Invest New Drugs; 2019 Jun; 37(3):498-506. PubMed ID: 30317534
[TBL] [Abstract][Full Text] [Related]
25. Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanoma.
Patel SP; Kim KB
Expert Opin Investig Drugs; 2012 Apr; 21(4):531-9. PubMed ID: 22394161
[TBL] [Abstract][Full Text] [Related]
26. Selumetinib shows promise in metastatic uveal melanoma.
Cancer Discov; 2013 Jul; 3(7):OF8. PubMed ID: 23847383
[TBL] [Abstract][Full Text] [Related]
27. Treating non-small cell lung cancer with selumetinib: an up-to-date drug evaluation.
Imyanitov EN; Levchenko EV; Kuligina ES; Orlov SV
Expert Opin Pharmacother; 2020 Nov; 21(16):1943-1953. PubMed ID: 32880495
[TBL] [Abstract][Full Text] [Related]
28. A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study.
Coleman RL; Sill MW; Thaker PH; Bender DP; Street D; McGuire WP; Johnston CM; Rotmensch J
Gynecol Oncol; 2015 Jul; 138(1):30-5. PubMed ID: 25887099
[TBL] [Abstract][Full Text] [Related]
29. A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors.
LoRusso PM; Infante JR; Kim KB; Burris HA; Curt G; Emeribe U; Clemett D; Tomkinson HK; Cohen RB
BMC Cancer; 2017 Mar; 17(1):173. PubMed ID: 28264648
[TBL] [Abstract][Full Text] [Related]
30. Randomized Phase II Trial and Tumor Mutational Spectrum Analysis from Cabozantinib versus Chemotherapy in Metastatic Uveal Melanoma (Alliance A091201).
Luke JJ; Olson DJ; Allred JB; Strand CA; Bao R; Zha Y; Carll T; Labadie BW; Bastos BR; Butler MO; Hogg D; Munster PN; Schwartz GK
Clin Cancer Res; 2020 Feb; 26(4):804-811. PubMed ID: 31558480
[TBL] [Abstract][Full Text] [Related]
31. A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy.
Bodoky G; Timcheva C; Spigel DR; La Stella PJ; Ciuleanu TE; Pover G; Tebbutt NC
Invest New Drugs; 2012 Jun; 30(3):1216-23. PubMed ID: 21594619
[TBL] [Abstract][Full Text] [Related]
32. BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer.
Ku BM; Jho EH; Bae YH; Sun JM; Ahn JS; Park K; Ahn MJ
Invest New Drugs; 2015 Feb; 33(1):12-21. PubMed ID: 25342139
[TBL] [Abstract][Full Text] [Related]
33. A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO).
Decker T; Overkamp F; Rösel S; Nusch A; Göhler T; Indorf M; Sahlmann J; Trarbach T
BMC Cancer; 2017 Jul; 17(1):499. PubMed ID: 28743247
[TBL] [Abstract][Full Text] [Related]
34. Active notch protects MAPK activated melanoma cell lines from MEK inhibitor cobimetinib.
Porcelli L; Mazzotta A; Garofoli M; Di Fonte R; Guida G; Guida M; Tommasi S; Azzariti A
Biomed Pharmacother; 2021 Jan; 133():111006. PubMed ID: 33202284
[TBL] [Abstract][Full Text] [Related]
35. A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC).
Tai WM; Yong WP; Lim C; Low LS; Tham CK; Koh TS; Ng QS; Wang WW; Wang LZ; Hartano S; Thng CH; Huynh H; Lim KT; Toh HC; Goh BC; Choo SP
Ann Oncol; 2016 Dec; 27(12):2210-2215. PubMed ID: 27681866
[TBL] [Abstract][Full Text] [Related]
36. Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance.
Ambrosini G; Pratilas CA; Qin LX; Tadi M; Surriga O; Carvajal RD; Schwartz GK
Clin Cancer Res; 2012 Jul; 18(13):3552-61. PubMed ID: 22550165
[TBL] [Abstract][Full Text] [Related]
37. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study.
Han HS; Diéras V; Robson M; Palácová M; Marcom PK; Jager A; Bondarenko I; Citrin D; Campone M; Telli ML; Domchek SM; Friedlander M; Kaufman B; Garber JE; Shparyk Y; Chmielowska E; Jakobsen EH; Kaklamani V; Gradishar W; Ratajczak CK; Nickner C; Qin Q; Qian J; Shepherd SP; Isakoff SJ; Puhalla S
Ann Oncol; 2018 Jan; 29(1):154-161. PubMed ID: 29045554
[TBL] [Abstract][Full Text] [Related]
38. A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study.
Bridgewater J; Lopes A; Beare S; Duggan M; Lee D; Ricamara M; McEntee D; Sukumaran A; Wasan H; Valle JW
BMC Cancer; 2016 Feb; 16():153. PubMed ID: 26912134
[TBL] [Abstract][Full Text] [Related]
39. Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies.
Hubbard JM; Yin J; Schenk EL; Qin R; Reid JM; Strand C; Fiskum J; Menefee M; Lin G; Doyle LA; Ivy P; Erlichman C; Adjei A; Haluska P; Costello BA
Invest New Drugs; 2022 Feb; 40(1):115-123. PubMed ID: 34515877
[TBL] [Abstract][Full Text] [Related]
40. Intermittent MEK inhibition for the treatment of metastatic uveal melanoma.
Khan S; Patel SP; Shoushtari AN; Ambrosini G; Cremers S; Lee S; Franks L; Singh-Kandah S; Hernandez S; Sender N; Vuolo K; Nesson A; Mundi P; Izar B; Schwartz GK; Carvajal RD
Front Oncol; 2022; 12():975643. PubMed ID: 36249046
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]